<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04166825</url>
  </required_header>
  <id_info>
    <org_study_id>292/B/2014/MP</org_study_id>
    <nct_id>NCT04166825</nct_id>
  </id_info>
  <brief_title>Ovarian Hyperstimulation and Fibrin Clot Properties.</brief_title>
  <official_title>The Impact of Different Ovarian Hyperstimulation Protocols on Coagulation and Fibrinolysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jagiellonian University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jagiellonian University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The impact evaluation of ovarian hyperstimulation on coagulation and fibrinolysis in
      infertile women.

      Comparative analysis between different ovarian stimulation protocols on thrombin formation
      and efficiency of fibrinolysis in women diagnosed with infertility.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infertility is a common problem. Assisted reproductive techniques (ART) increases the chance
      of getting pregnant by couples undergoing such treatment. Unfortunately, the numer of live
      births after ART remains still low. Over the past three decades, physicians have tried to
      improve infertility diagnosis and increase its successful treatment. An effort aimed at
      increasing effectivenes of diagnosis resulted in hypothesis that one of probable reasons of
      infertility may be the occurrence of microclots, which worsen implantation and embryos
      development. There are currently no published studies describing the effects of different
      ovarian hyperstimulation protocols on hemostasis (coagulation and fibrinolysis).

      The parameters of thrombin generation and efficiency of fibrinolysis will be evaluated in
      women qualified for ovarian hyperstimulation. The study may improve the effectiveness of ART.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 18, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fibrin clot properties before and after the ovarian hyperstimulation.</measure>
    <time_frame>4 months</time_frame>
    <description>Coagulation (endogenous thrombin potential) and fibrinolysis (F1+2, clot lysis time)parameters assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endometriosis and fibrin clot properties.</measure>
    <time_frame>1 cycle</time_frame>
    <description>Changes of fibrin clot properties before and after ovarian hyperstimulation in women with endometriosis - Coagulation (endogenous thrombin potential) and fibrinolysis (F1+2, clot lysis time)parameters assessment.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Fibrin Blood Clot</condition>
  <condition>Infertility, Female</condition>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Long protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ovarian hyperstimulation started on day 2 or 3 of the cycle with daily subcutaneous injections of recombinant human FSH (follitropin α, Gonal F®, Merck Serono) and/or urinary human menopausal gonadotropin (menotropin, Menopur®, Ferring GmbH) or mixed recombinant human FSH/LH (Pergoveris®, Merck Serono) with a starting dose of 87.5-250 IE/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Short protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ovarian hyperstimulation with a GnRH-antagonist consisted of the use of ganirelix (Orgalutran®, MSD) from the 6th day of stimulation until it's end at the daily dose of 0.25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clomiphene citrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ovarian stimulation with clomiphene citrate (Clostilbegyt®, EGIS) 50 mg daily per os form 3rd to 7th day of the cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ovarian stimulation with letrozole (Lametta®, Vipharm) 2.5 mg daily per os form 3rd to 7th day of the cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gonadotropins</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ovarian hyperstimulation started on day 2 or 3 of the cycle with daily subcutaneous injections of recombinant human FSH (follitropin α, Gonal F®, Merck Serono).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>fibrin clot properties</intervention_name>
    <description>Assessment of thrombin generation and efficiency of fibrinolysis.</description>
    <arm_group_label>Clomiphene citrate</arm_group_label>
    <arm_group_label>Gonadotropins</arm_group_label>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_label>Long protocol</arm_group_label>
    <arm_group_label>Short protocol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  infertility defined based on the WHO 2010 criteria

        Exclusion Criteria:

          -  ovarian involvement

          -  oral contraceptives use within previous 3 months

          -  dienogest therapy within 3 months until ART

          -  thrombotic events in the medical history

          -  severe hypertension

          -  diabetes mellitus

          -  the presence of known VTE risk factors, including obesity, recent major surgery with
             prolonged immobilization or trauma,

          -  deficiency of antithrombin, protein C or protein S,

          -  antiphospholipid syndrome,

          -  known malignancy,

          -  any chronic inflammatory diseases (e.g. rheumatoid arthritis)

          -  advanced chronic renal disease (estimated glomerular filtration rate [eGFR] &lt;30
             ml/min),

          -  international normalized ratio (INR) more than 1.2 at the day of blood draw

          -  pregnancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Gynecological Endocrinology Jagiellonian University Medical College</name>
      <address>
        <city>Kraków</city>
        <state>Małopolska</state>
        <zip>30-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Piróg, MD, PhD</last_name>
      <phone>604514915</phone>
      <email>magda.m.pulka@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Olga Kacalska - Janssen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanna Natorska, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Jach, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jakub Wyroba, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jagiellonian University</investigator_affiliation>
    <investigator_full_name>Magdalena Piróg, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>coagulation</keyword>
  <keyword>fibrinolysis</keyword>
  <keyword>ovarian hyperstimulation</keyword>
  <keyword>infertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

